Immediate Impact
4 from Science/Nature 57 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Engineering protein-based therapeutics through structural and chemical design
2023 Standout
Works of Nora Ku being referenced
The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
2017
Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Nora Ku | 97 | 123 | 167 | 248 | 201 | 24 | 578 | |
| DG Poplack | 133 | 84 | 262 | 138 | 210 | 22 | 706 | |
| Cecilia Carbone | 57 | 37 | 157 | 193 | 125 | 28 | 588 | |
| Gerald L. Messerschmidt | 55 | 59 | 173 | 122 | 163 | 26 | 548 | |
| AR Zander | 81 | 68 | 229 | 274 | 176 | 21 | 631 | |
| Uri Mintz | 192 | 60 | 138 | 284 | 112 | 34 | 688 | |
| Chimene Kesserwan | 91 | 88 | 174 | 151 | 85 | 24 | 640 | |
| Hideaki Mizoguchi | 139 | 39 | 174 | 273 | 313 | 30 | 699 | |
| J. Graham Sharp | 94 | 38 | 248 | 253 | 113 | 26 | 626 | |
| Nicolas Leupin | 115 | 46 | 128 | 163 | 169 | 29 | 687 | |
| R S Metzgar | 82 | 34 | 152 | 129 | 312 | 30 | 619 |
All Works
Loading papers...